Myriad Genetics (MYGN) Total Non-Current Liabilities (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Total Non-Current Liabilities data on file, last reported at $334.6 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $334.6 million, up 11.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $334.6 million (up 11.83% YoY), and the FY2025 annual result was $336.7 million, up 3.82% from the prior year.
• Total Non-Current Liabilities slipped to $334.6 million in Q1 2026 per MYGN's latest filing, from $336.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $440.6 million in Q2 2023 and troughed at $258.1 million in Q2 2022.
• A 5-year average of $320.4 million and a median of $315.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 39.54% in 2022, then surged 70.71% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $269.0 million in 2022, then climbed by 17.17% to $315.2 million in 2023, then gained by 2.89% to $324.3 million in 2024, then grew by 3.82% to $336.7 million in 2025, then retreated by 0.62% to $334.6 million in 2026.
• Business Quant data shows MYGN's Total Non-Current Liabilities at $334.6 million in Q1 2026, $336.7 million in Q4 2025, and $353.6 million in Q3 2025.